NO20051942D0 - Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer - Google Patents

Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer

Info

Publication number: NO20051942D0
Authority: NO; Norway
Prior art keywords: cindazol; phenols; ligands; substituted; treatment
Prior art date: 2002-09-25

Application number

NO20051942A

Other languages

English (en)

Other versions

NO20051942L (no

Inventor

Robert John Steffan

Mark Anthony Ashwell

Edward Martin Matelan

William Ronad Solvibile

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-25

Filing date

2005-04-20

Publication date

2005-04-20

2005-04-20 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-04-20 Publication of NO20051942D0 publication Critical patent/NO20051942D0/no

2005-06-14 Publication of NO20051942L publication Critical patent/NO20051942L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Toxicology (AREA)

NO20051942A 2002-09-25 2005-04-20 Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer NO20051942L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41393102P	2002-09-25	2002-09-25
PCT/US2003/030252 WO2004031159A1 (en)	2002-09-25	2003-09-24	Substituted 4-(indazol-3-yl)phenols as estrogen receptor (er) ligands and their use in the treatment of inflammatory diseases

Publications (2)

Publication Number	Publication Date
NO20051942D0 true NO20051942D0 (no)	2005-04-20
NO20051942L NO20051942L (no)	2005-06-14

Family

ID=32069719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051942A NO20051942L (no)	2002-09-25	2005-04-20	Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer

Country Status (21)

Country	Link
US (2)	US7241791B2 (no)
EP (1)	EP1542976B1 (no)
JP (1)	JP4459813B2 (no)
KR (1)	KR20050053702A (no)
CN (2)	CN101054364A (no)
AR (1)	AR041378A1 (no)
AT (1)	ATE422202T1 (no)
AU (1)	AU2003276940A1 (no)
BR (1)	BR0314475A (no)
CA (1)	CA2499736A1 (no)
CR (1)	CR7769A (no)
DE (1)	DE60326077D1 (no)
DK (1)	DK1542976T3 (no)
EC (1)	ECSP055704A (no)
ES (1)	ES2319519T3 (no)
MX (1)	MXPA05003275A (no)
NO (1)	NO20051942L (no)
RU (1)	RU2005109387A (no)
TW (1)	TW200409759A (no)
WO (1)	WO2004031159A1 (no)
ZA (1)	ZA200502462B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004050634A1 (en) *	2002-12-02	2004-06-17	F. Hoffmann-La Roche Ag	Indazole derivatives as crf antagonists
JP2005089457A (ja) *	2003-09-03	2005-04-07	Yung Shin Pharmaceutical Industry Co Ltd	骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
WO2005063222A1 (ja) *	2003-12-26	2005-07-14	Kyowa Hakko Kogyo Co., Ltd.	Hsp90ファミリー蛋白質阻害剤
AU2005271737A1 (en) *	2004-08-03	2006-02-16	Wyeth	Indazoles useful in treating cardiovascular diseases
DE102004039280A1 (de) *	2004-08-13	2006-02-23	Merck Patent Gmbh	1,5-Diphenyl-pyrazole
RU2007108713A (ru)	2004-09-02	2008-10-10	Вайет (Us)	Фенантридинкарбонилфенолы в качестве модуляторов цитокина
EP1647549A1 (en) *	2004-10-14	2006-04-19	Laboratoire Theramex	Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7601847B2 (en) *	2004-10-26	2009-10-13	Wyeth	Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en) *	2004-11-01	2006-07-01	Wyeth Corp	[(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
CN100516049C (zh) *	2004-11-16	2009-07-22	永信药品工业股份有限公司	抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
EP1856151A2 (en)	2005-01-19	2007-11-21	Wyeth	Estrogen receptor structure
TWI411602B (zh)	2006-09-12	2013-10-11	Gilead Sciences Inc	製造整合酶抑制劑的方法及彼所用的中間物
US7919581B2 (en)	2007-07-31	2011-04-05	Burnham Institute For Medical Research	Bi-dentate compounds as kinase inhibitors
AR068403A1 (es)	2007-09-11	2009-11-18	Gilead Sciences Inc	Proceso e intermediarios para la preparacion de inhibidores de integrasa
CN102089302A (zh)	2008-07-17	2011-06-08	旭化成制药株式会社	含氮二环性杂环化合物
US20110229471A1 (en)	2008-11-26	2011-09-22	Cedars-Sinai Medical Center	Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en)	2008-12-24	2010-07-01	Cedars-Sinai Medical Center	Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
TWI476188B (zh)	2010-05-27	2015-03-11	Ube Industries	新穎吲唑衍生物或其鹽及其製造中間體、以及使用其之抗氧化劑
AU2013296289B2 (en)	2012-08-03	2017-10-05	Gilead Sciences, Inc.	Process and intermediates for preparing integrase inhibitors
JP2014133739A (ja) *	2012-12-12	2014-07-24	Dainippon Sumitomo Pharma Co Ltd	インダゾール誘導体またはピロロピリジン誘導体からなる医薬
BR112015024752A2 (pt)	2013-03-27	2017-07-18	Cedars Sinai Medical Center	mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
WO2015010108A1 (en)	2013-07-19	2015-01-22	Cedars-Sinai Medical Center	Signature of tl1a (tnfsf15) signaling pathway
KR102412146B1 (ko) *	2015-02-11	2022-06-22	주식회사 아이엔테라퓨틱스	소디움 채널 차단제
JP7082945B2 (ja)	2016-03-17	2022-06-09	シーダーズ―シナイメディカルセンター	Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CN106511350A (zh) *	2016-09-26	2017-03-22	张德芳	6‑羟基‑7‑芳甲酰基喹啉酮类化合物在治疗溃疡性结肠炎中的应用
JP7090639B2 (ja)	2017-04-11	2022-06-24	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	フッ素置換されたインダゾール化合物及びその使用
EP3796905B1 (en)	2018-05-23	2025-08-06	The Board of Trustees of the University of Illinois	Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (ms) and other demyelinating, inflammatory and neurodegenerative diseases
CN118772140A (zh) *	2023-04-07	2024-10-15	四川大学	一类化合物及其在治疗hDHODH介导的疾病中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01180878A (ja)	1988-01-11	1989-07-18	Yoshitomi Pharmaceut Ind Ltd	縮合ピラゾール化合物
JPH027066A (ja)	1988-06-27	1990-01-11	Hitachi Chem Co Ltd	電子写真感光体
DK181190D0 (da)	1990-07-30	1990-07-30	Lundbeck & Co As H	3-aryl-indol- eller 3-aryl-indazolderivater
JPH05331168A (ja)	1992-05-29	1993-12-14	Yoshitomi Pharmaceut Ind Ltd	Ｎ−オキシドを有する新規な縮合型ピラゾール化合物
WO1994007865A1 (fr)	1992-09-29	1994-04-14	Yoshitomi Pharmaceutical Industries, Ltd.	Compose d'ester carboxylique
JPH06206872A (ja)	1992-10-06	1994-07-26	Yoshitomi Pharmaceut Ind Ltd	縮合型ピラゾール化合物
CA2190708A1 (en)	1995-12-08	1997-06-09	Johannes Aebi	Aminoalkyl substituted benzo-heterocyclic compounds
US6080773A (en)	1997-10-14	2000-06-27	Akzo Nobel, N.V.	Benzylamine derivatives which are useful in treating psychiatric disorders
JP4324988B2 (ja) *	1997-12-17	2009-09-02	東洋紡績株式会社	発毛誘導剤および発毛方法
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
JP2004524289A (ja)	2000-12-22	2004-08-12	アストラゼネカ・アクチエボラーグ	治療化合物
CA2440842A1 (en)	2001-04-16	2002-10-24	Eisai Co., Ltd.	Novel 1h-indazole compounds
UA83620C2 (ru) *	2001-12-05	2008-08-11	Уайт	Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6774248B2 (en) *	2001-12-18	2004-08-10	Wyeth	Substituted 2-phenyl benzofurans as estrogenic agents
US20040002524A1 (en) *	2002-06-24	2004-01-01	Richard Chesworth	Benzimidazole compounds and their use as estrogen agonists/antagonists
AU2005271737A1 (en) *	2004-08-03	2006-02-16	Wyeth	Indazoles useful in treating cardiovascular diseases

2003
- 2003-09-22 TW TW092126068A patent/TW200409759A/zh unknown
- 2003-09-24 DK DK03799289T patent/DK1542976T3/da active
- 2003-09-24 WO PCT/US2003/030252 patent/WO2004031159A1/en not_active Ceased
- 2003-09-24 AR ARP030103479A patent/AR041378A1/es unknown
- 2003-09-24 EP EP03799289A patent/EP1542976B1/en not_active Expired - Lifetime
- 2003-09-24 JP JP2004541738A patent/JP4459813B2/ja not_active Expired - Fee Related
- 2003-09-24 AT AT03799289T patent/ATE422202T1/de not_active IP Right Cessation
- 2003-09-24 RU RU2005109387/04A patent/RU2005109387A/ru not_active Application Discontinuation
- 2003-09-24 CN CNA2007100978048A patent/CN101054364A/zh active Pending
- 2003-09-24 AU AU2003276940A patent/AU2003276940A1/en not_active Abandoned
- 2003-09-24 CN CNB038228491A patent/CN1321984C/zh not_active Expired - Fee Related
- 2003-09-24 CA CA002499736A patent/CA2499736A1/en not_active Abandoned
- 2003-09-24 ES ES03799289T patent/ES2319519T3/es not_active Expired - Lifetime
- 2003-09-24 MX MXPA05003275A patent/MXPA05003275A/es active IP Right Grant
- 2003-09-24 DE DE60326077T patent/DE60326077D1/de not_active Expired - Lifetime
- 2003-09-24 BR BR0314475-5A patent/BR0314475A/pt not_active IP Right Cessation
- 2003-09-24 US US10/670,646 patent/US7241791B2/en not_active Expired - Fee Related
- 2003-09-24 KR KR1020057005296A patent/KR20050053702A/ko not_active Ceased
2005
- 2005-03-23 EC EC2005005704A patent/ECSP055704A/es unknown
- 2005-03-24 ZA ZA200502462A patent/ZA200502462B/en unknown
- 2005-03-28 CR CR7769A patent/CR7769A/es not_active Application Discontinuation
- 2005-04-20 NO NO20051942A patent/NO20051942L/no unknown
2007
- 2007-05-16 US US11/749,494 patent/US20070225349A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2004031159A1 (en)	2004-04-15
CN101054364A (zh)	2007-10-17
AU2003276940A1 (en)	2004-04-23
CA2499736A1 (en)	2004-04-15
EP1542976B1 (en)	2009-02-04
DE60326077D1 (de)	2009-03-19
TW200409759A (en)	2004-06-16
RU2005109387A (ru)	2006-01-20
CN1692102A (zh)	2005-11-02
JP4459813B2 (ja)	2010-04-28
CN1321984C (zh)	2007-06-20
MXPA05003275A (es)	2005-09-12
EP1542976A1 (en)	2005-06-22
US7241791B2 (en)	2007-07-10
JP2006505544A (ja)	2006-02-16
AR041378A1 (es)	2005-05-11
NO20051942L (no)	2005-06-14
ES2319519T3 (es)	2009-05-08
ECSP055704A (es)	2005-07-06
CR7769A (es)	2005-08-12
US20040167127A1 (en)	2004-08-26
KR20050053702A (ko)	2005-06-08
US20070225349A1 (en)	2007-09-27
ZA200502462B (en)	2006-09-27
ATE422202T1 (de)	2009-02-15
DK1542976T3 (da)	2009-05-11
BR0314475A (pt)	2005-08-09

Publication	Publication Date	Title
NO20051942D0 (no)	2005-04-20	Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
DK1761266T3 (da)	2013-08-05	Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
NO20055516L (no)	2005-11-22	Kannabinoidreceptorligander og anvendelser derav
DK1917246T3 (da)	2010-03-29	Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
EE200500011A (et)	2005-06-15	Indasoolid, bensotiasoolid ja bensoisotiasoolid, nende valmistamine ning kasutamine
NO20052512L (no)	2005-05-25	Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
NO20081842L (no)	2008-07-08	Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DK1701941T3 (da)	2012-08-13	Forbindelser til behandling af sygdomme med celleproliferation
EP1737482A4 (en)	2010-09-15	COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
AP2005003283A0 (en)	2005-06-30	Indole derivatives useful for the treatment os diseases
HRP20160880T1 (hr)	2016-09-23	Formulacija obložene tablete i postupak
NO20043370L (no)	2004-09-28	N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
AP2006003669A0 (en)	2006-06-30	Sulfonamide derivatives for the treatment of diseases
DK1487828T3 (da)	2009-02-02	Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
NO20034864D0 (no)	2003-10-31	Preparat for behandling av legemiddelindusert forstoppelse med 15-keto-prostaglandiner
NO20041214L (no)	2004-06-24	Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1478438T3 (da)	2012-08-27	Fremgangsmåder og sammensætninger til behandling af astma
NO20014648D0 (no)	2001-09-25	Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer
IL182767A0 (en)	2007-09-20	S-mirtazapine for the treatment of hot flush
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
IS8497A (is)	2006-06-02	Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
IS8072A (is)	2005-10-13	Miðlar úr bak kólesteról flutningi í meðferð á kólesterólhækkun